Biogen, Eisai AD readout leads to stock dive

Biogen Inc. (NASDAQ:BIIB) sank $39.09 (10%) to $344.74 on Thursday after reporting detailed data from a Phase II trial of Alzheimer's disease candidate BAN2401. Although the data

Read the full 279 word article

User Sign In